A Phase 3 interventional study of VRDN-003 and Placebo in Thyroid Eye Disease, sponsored by Viridian Therapeutics, Inc.. Active, not recruiting at 60 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-18.
Sponsored by Viridian Therapeutics, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies in Graves Ophthalmopathy with a site in United States — 12 open to participants now, 18 under way, 8 of them phase 3. Graves Ophthalmopathy · United States.
Among the 53 studies in Graves Ophthalmopathy with a site in United States, this one is the 4th largest by enrollment of the 47 interventional ones that give a count, is one of 11 that started in 2024, is one of 21 in phase 3, reaches primary completion later than 2 of the 17 other live ones, and was the 39th registered.
199 studies on the registry are indexed under Graves Ophthalmopathy; 58 are open to participants now.
Browse Graves Ophthalmopathy studies →12 of the 53 studies in Graves Ophthalmopathy with a site in United States are open now. Recruiting first, the newest first:
Minghui Pharmaceutical (Hangzhou) Ltd · Sites in United States
Ages 18–75
Minghui Pharmaceutical (Hangzhou) Ltd · Sites in United States
Ages 18–75
Sling Therapeutics, Inc. · Sites in United States
Ages 18+
Ethyreal Bio, Inc. · Sites in United States
Ages 18+ · Healthy volunteers
Amgen · Sites in United States, Poland, Spain and 1 more country
Ages 18–99
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 38 Graves Ophthalmopathy studies recruiting now, 8 (21%) set no upper age limit and 16 (42%) stop at 75 or younger; 1 takes children under 18; 9 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 14 · Phase 3 24 · Phase 4 5
First in 2006; this study’s year is marked. 11 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 204 is above the median of 63 across 146 interventional studies indexed under Graves Ophthalmopathy.
Median enrollment 84 across the 47 interventional studies, 100 across the 5 observational. Of the 33 that completed or were terminated, 17 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
42 of 53 have an industry lead sponsor. The 10 most frequent:
Viridian Therapeutics, Inc. is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
Viridian Therapeutics, Inc. has 9 studies filed under Graves Ophthalmopathy — fewer than ten, so there is no comparison to draw.
4 of the studies in Graves Ophthalmopathy with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06401044AmgenA Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease | 2027-01-06 |
| NCT07832136Viridian Therapeutics, Inc.An Open-Label Trial of Veligrotug in Participants With Thyroid Eye Disease Who Previously Responded to Teprotumumab | 2027-04 |
| NCT07623837THYROSCOPE INC.Clinical Validation of AI-Based Quantitative Eye Movement Analysis From Smartphone 9-Gaze Videos (Glandy EOM) | 2027-06-30 |
| NCT07623993THYROSCOPE INC.Prospective Observational Study of Smartphone-Based AI Self-Monitoring During Non-Surgical Treatment for Thyroid Eye Disease (THYROSCOPE) | 2027-06-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 53 studies in Graves Ophthalmopathy with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, VRDN-003, in participants with chronic Thyroid Eye Disease (TED).
This is a randomized (meaning participants will be assigned to study arms by chance), double-masked (meaning study doctor and participant will not know which study arm participant is assigned to), placebo-controlled study that will include participants with chronic TED. The key objectives of this study are to determine if VRDN-003 is efficacious, safe and tolerable when administered as subcutaneous/SC injections every 4 weeks or every 8 weeks compared to placebo in participants with chronic TED.
Participants who do not have a meaningful response at Week 24 (irrespective of the initial treatment arm) may be eligible to receive additional subcutaneous injections of VRDN-003.
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: There are additional eligibility criteria for participants who do not have a meaningful response at Week 24 (irrespective of initial treatment arm) who may receive additional injections of VRDN-003. These are described in the protocol.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
6 subcutaneous administrations of VRDN-003
Drug: VRDN-003
3 subcutaneous administrations of VRDN-003 and 3 subcutaneous administrations of placebo
Drug: VRDN-003 · Drug: Placebo
6 subcutaneous administrations of placebo
Drug: Placebo
VRDN-003 is an investigational, subcutaneously administered, humanized monoclonal antibody directed against the Insulin-like Growth Factor-1 receptor (IGF-1R).
All participants will receive the same number of injections to maintain masking. Masking will be maintained by the use of placebo injections that appear identical to VRDN-003 injections.
Title: Proptosis Responder Rate in the most proptotic eye as measured by exophtalmometer
Description: Proportion of participants with a ≥2 mm reduction from baseline in proptosis in the most proptotic eye as measured by exophtalmometer \[without a corresponding increase of ≥2 mm in the other eye\]
Time frame: At Week 24
Change from baseline in proptosis in the most proptotic eye as measured by exophthalmometer
Change from baseline in proptosis in the most proptotic eye as measured by exophthalmometer
Time frame: At Week 24
Proptosis Responder Rate in the most proptotic eye as measured by MRI
Proportion of participants with a ≥2 mm reduction from baseline in proptosis in the most proptotic eye as measured by MRI \[without a corresponding increase of ≥2 mm in the other eye\]
Time frame: At Week 24
Change from baseline in proptosis in the most proptotic eye as measured by MRI
Change from baseline in proptosis in the most proptotic eye as measured by MRI
Time frame: At Week 24
Overall Responder Rate in the most proptotic eye as measured by exophthalmometer
Proportion of participants with a ≥2 mm reduction from baseline in proptosis in the most proptotic eye as measured by exophthalmometer \[without a corresponding increase of ≥2 mm in the other eye\] AND no worsening in Clinical Activity Score (CAS) from baseline in the most proptotic eye \[without a corresponding increase of ≥2 points in the other eye\]
Time frame: At Week 24
Diplopia Responder Rate for participants with baseline Diplopia Score greater than 0
Proportion of participants with a reduction in Diplopia Score of ≥1 from baseline (for participants with baseline Diplopia Score greater than 0)
Time frame: At Week 24
Diplopia Resolution Rate for participants with baseline Diplopia Score greater than 0
Proportion of participants with a reduction in Diplopia Score to 0 from baseline (for participants with baseline Diplopia Score greater than 0)
Time frame: At Week 24
Ran from Aug 2024 to primary completion in Mar 2026, 18 months.
Of 29 phase 3 interventional studies under Graves Ophthalmopathy, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 25. This study's 18 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Elegrobart
Viridian Therapeutics, Inc.